Q2 EPS Estimates for Traws Pharma Raised by HC Wainwright

Traws Pharma, Inc. (NASDAQ:TRAW) – Research analysts at HC Wainwright boosted their Q2 2026 earnings per share estimates for shares of Traws Pharma in a research report issued to clients and investors on Wednesday, May 20th. HC Wainwright analyst B. Folkes now expects that the company will post earnings per share of ($0.41) for the quarter, up from their prior estimate of ($0.54). HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Traws Pharma’s current full-year earnings is ($2.72) per share. HC Wainwright also issued estimates for Traws Pharma’s Q3 2026 earnings at ($0.20) EPS, Q4 2026 earnings at ($0.23) EPS, FY2026 earnings at ($1.31) EPS, FY2027 earnings at ($0.55) EPS, FY2028 earnings at ($0.11) EPS and FY2029 earnings at $0.24 EPS.

Traws Pharma (NASDAQ:TRAW) last released its earnings results on Friday, May 15th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.39.

Other analysts have also recently issued research reports about the stock. LADENBURG THALM/SH SH upgraded shares of Traws Pharma to a “strong-buy” rating in a research note on Friday, January 30th. Weiss Ratings lowered shares of Traws Pharma from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, May 15th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $8.00.

Traws Pharma Price Performance

NASDAQ:TRAW opened at $1.49 on Friday. The firm has a market cap of $15.14 million, a price-to-earnings ratio of -0.88 and a beta of 1.47. The firm’s fifty day moving average price is $1.68 and its 200 day moving average price is $1.82. Traws Pharma has a 1-year low of $1.00 and a 1-year high of $3.27.

Insider Activity

In related news, major shareholder Orbimed Advisors Llc acquired 597,729 shares of the firm’s stock in a transaction that occurred on Thursday, April 16th. The shares were acquired at an average price of $1.67 per share, with a total value of $998,207.43. Following the completion of the purchase, the insider directly owned 1,203,250 shares in the company, valued at approximately $2,009,427.50. The trade was a 98.71% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 14.00% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Traws Pharma

Hedge funds have recently modified their holdings of the company. Two Sigma Investments LP grew its holdings in shares of Traws Pharma by 37.1% during the third quarter. Two Sigma Investments LP now owns 22,018 shares of the company’s stock worth $41,000 after buying an additional 5,955 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Traws Pharma by 41.9% during the fourth quarter. Geode Capital Management LLC now owns 61,653 shares of the company’s stock valued at $70,000 after buying an additional 18,213 shares during the period. State Street Corp acquired a new stake in Traws Pharma during the fourth quarter worth approximately $29,000. XTX Topco Ltd boosted its position in Traws Pharma by 294.2% during the fourth quarter. XTX Topco Ltd now owns 42,210 shares of the company’s stock worth $48,000 after acquiring an additional 31,502 shares during the last quarter. Finally, Seven Fleet Capital Management LP purchased a new stake in Traws Pharma in the 4th quarter worth approximately $56,000. 7.95% of the stock is owned by institutional investors and hedge funds.

About Traws Pharma

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.